Clinical trial
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in…
NCT00192647 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00192647 |
|---|---|
| Title | A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection |
| Official title | A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1 |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | PEG-IFN alfa-2a, Ribavirin |
| Enrollment | 896 |
| Start date | Aug 1, 2004 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 4, 2016 |
| Countries | Argentina, Australia, Canada, Mexico, New Zealand, Thailand |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: